Krystal Biotech (KRYS) Bank of America Global Healthcare Conference 2026 summary

Financial performance and business model

• Achieved 11-12 consecutive quarters of positive EPS and gross margins in the 90-95% range, reflecting a sustainable business model uncommon in biotech.

• Global launch, especially ex-U.S., has exceeded expectations, with strong value propositions in France, Germany, and Japan; launches in Italy and Spain are ahead of schedule for the second half of the year.

• U.S. market continues to grow, with 40-50 new reimbursement approvals per quarter, and cost structure remains stable due to small teams per country.

• Operating expenses are guided to remain similar through 2026, even as new assets enter the clinic.

VYJUVEK launch and market dynamics

• U.S. penetration is at 60% of identified patients (about 1,200), with ongoing efforts to reach the full prevalence estimate of 3,000.

• Patient compliance and positive experiences are driving long-term retention, with stop-and-start trends expected to persist.

• The $900K reimbursement cap in the U.S. is largely being phased out as payer confidence grows.

• Ex-U.S. launches in Japan, Germany, and France are progressing well, with pricing negotiations ongoing and positive outcomes expected.

• Physician awareness in Europe is high, aided by shared U.S. experiences, accelerating launches in Italy and Spain.

Revenue recognition and pricing strategy

• Patient numbers in Europe are estimated via vial distribution due to privacy constraints, but revenue is now split out by region.

• Italy and Spain will have negotiated prices before launch, with no accruals, and patient prevalence is estimated at 275-350 per country.

• Most Favored Nation (MFN) pricing is a key consideration in ex-U.S. negotiations, with long-term U.S. business impact in mind.